ArticleMolecular biology reports2026
Endolysosomal iron-associated vesicular changes and ferroptosis-related vulnerability in VPS13A-knockdown cells.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundChorein, the VPS13A gene product whose loss causes chorea-acanthocytosis (ChAc, VPS13A disease), has been implicated in ferroptosis-related vulnerability, but the organellar basis of this phenotype remains unclear. Using VPS13A knockdown (VPS13A-KD) human embryonic kidney 293 (HEK293) cells, we previously found that chorein reduction is associated with impaired ferrous iron (Fe(II)) efflux, increased lipid peroxidation, reduced glutathione peroxidase 4 (GPX4) levels in the cytosolic fraction, and ferrostatin-1-suppressible cell death. METHODS AND
resultsIn this study, we found that VPS13A-KD cells exhibited significantly elevated lipid peroxidation following treatment with the oxidant tert-butyl hydroperoxide (tBHP), and this increase was markedly suppressed by the iron chelator deferasirox (DFX) or the antioxidant vitamin E (α-tocopherol). DFX treatment induced enlarged vesicular structures in VPS13A-KD cells, showing spatial overlap of Fe(II), lipid peroxidation, and lysosomal signals, suggesting altered vesicular responses to oxidative stress. These enlarged vesicles showed partial spatial overlap with the late endosomal marker RAB7A, consistent with involvement of the late endosomal-lysosomal system. VPS13A-KD cells also exhibited mitochondrial morphological abnormalities, and a subset of enlarged vesicles overlapped with the mitochondrial outer membrane protein TOMM20, suggesting altered interactions between mitochondria and endolysosomal compartments.
conclusionsThese findings suggest that lysosome-associated vesicular changes in VPS13A-KD cells may be associated with altered iron handling, consistent with our previous finding of impaired Fe(II) efflux. Although DFX reduced lipid peroxidation, it was also associated with prominent vesicular alterations, the significance of which remains to be clarified. In contrast, α-tocopherol attenuated oxidative injury without prominent vesicular accumulation in this model.
Indexed as
Identifiers
42663743What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.